AstraZeneca PLC filed a Form 6-K on 16 November 2026 disclosing that its drug Baxfendy (baxdrostat) received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP), recommending approval in the European Union for the treatment of adults with arterial hypertension insufficiently controlled with at least two antihypertensive medicinal products.

Key Highlights

  • CHMP positive opinion: The EMA's CHMP recommended Baxfendy (baxdrostat) for approval in the EU for adults with hypertension uncontrolled on at least two antihypertensive medicines.
  • First-in-class potential: According to the filing, if approved, Baxfendy would be the first and only aldosterone synthase inhibitor (ASI) in the EU.
  • BaxHTN trial result: Baxfendy 2mg reduced mean seated systolic blood pressure by 15.7 mmHg from baseline at week 12, with a placebo-adjusted reduction of 9.8 mmHg (95% CI, -12.6 to -7.0; p<0.001).
  • Bax24 trial result: Baxfendy 2mg reduced 24-hour ambulatory systolic blood pressure by 16.6 mmHg from baseline at week 12, with a placebo-adjusted reduction of 14.0 mmHg (95% CI, -17.2, -10.8; p<0.0001).
  • Existing approvals: The filing states Baxfendy is already approved in the US and other countries, with regulatory filings under review in Japan and China.
  • Patient population context: The filing cites approximately 70 million adults across Europe with hypertension that remains uncontrolled despite treatment.

AstraZeneca's Baxfendy Recommendation: EU Trial Data and Regulatory Context

AstraZeneca PLC (NYSE:AZN) disclosed in a Form 6-K for the month of November 2026 that the CHMP of the European Medicines Agency issued a positive opinion recommending Baxfendy (baxdrostat) for approval in the EU. The recommended indication covers adults with arterial hypertension insufficiently controlled with at least two antihypertensive medicinal products. The filing states the CHMP based its opinion on results from two pivotal Phase III trials demonstrating "statistically significant and clinically meaningful reductions" in systolic blood pressure.

In the BaxHTN Phase III trial, published in the New England Journal of Medicine according to the filing, Baxfendy 2mg produced an absolute reduction from baseline in mean seated systolic blood pressure of 15.7 mmHg (95% CI, -17.6 to -13.7) and a placebo-adjusted reduction of 9.8 mmHg (95% CI, -12.6 to -7.0; p<0.001) at week 12. A total of 796 patients were randomised in a 1:1:1 ratio to receive Baxfendy 2mg, 1mg, or placebo once daily on top of standard of care. In the Bax24 Phase III trial, published in The Lancet according to the filing, the absolute reduction from baseline in 24-hour ambulatory systolic blood pressure was 16.6 mmHg (95% CI, -18.8 to -14.3) and the placebo-adjusted reduction was 14.0 mmHg (95% CI, -17.2, -10.8; p<0.0001) at week 12.

The filing states that Baxfendy "was generally well-tolerated in the trials, with no unanticipated safety findings." AstraZeneca describes baxdrostat as "a first-in-class, highly selective and potent ASI designed to lower blood pressure in a new way by specifically inhibiting the production of aldosterone." Ruud Dobber, Executive Vice President and President of AstraZeneca's BioPharmaceuticals Business Unit, is quoted in the filing referencing the company's "2030 ambition to bring 20 new medicines to the world."

What Was Disclosed

AstraZeneca filed a Form 6-K dated 16 November 2026 reporting a CHMP positive opinion for Baxfendy in the EU, supported by Phase III data showing statistically significant reductions in systolic blood pressure and noting the drug's existing US approval and pending filings in Japan and China.